8 active not recruiting, 4 completed, 2 recruiting, 2 terminated. 16 Phase 2, 5 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Active not recruiting 8, Completed 4, Recruiting 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 5 | Completed 2, Recruiting 2, Not yet recruiting 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Refractory Rhabdomyosarcoma: new trials by email Literature Review of Refractory Rhabdomyosarcoma trials Research Report on Refractory Rhabdomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide - Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2020-08-19 | 2025-06-29 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients Cisplatin, Cytoreductive Surgery, Doxorubicin - Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm | Early Phase 1 | Terminated | Mayo Clinic | 2 | 2019-11-08 | 2025-02-20 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-06 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Adavosertib, Irinotecan Hydrochloride - Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 76 | 2014-03-28 | 2023-09-26 |
Rhabdomyosarcoma (17) · Neuroblastoma (14) · Neuroectodermal Tumors, Primitive, Peripheral (12) · Osteosarcoma (12) · Sarcoma (12) · Hepatoblastoma (11) · Wilms Tumor (11) · Lymphoma, Non-Hodgkin (10) · Medulloblastoma (10) · Rhabdoid Tumor (10) · Ependymoma (9) · Glioma (9) · Histiocytosis, Langerhans-Cell (9) · Sarcoma, Ewing (9) · Central Nervous System Neoplasms (6)
Myosarcoma (17) · Neoplasms by Histologic Type (17) · Neoplasms, Connective and Soft Tissue (17) · Neoplasms, Muscle Tissue (17) · Neoplasms (16) · Neoplasms, Glandular and Epithelial (16) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Nerve Tissue (15) · Neuroectodermal Tumors (15) · Neoplasms by Site (14) · Neoplasms, Connective Tissue (14) · Neoplasms, Neuroepithelial (14) · Neoplasms, Bone Tissue (13) · Neuroectodermal Tumors, Primitive (13) · Female Urogenital Diseases (12)
Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · X-Rays (5) · Nuclear Medicine Department, Hospital (4) · Phantoms, Imaging (4) · Biopsy (3) · Temozolomide (2) · ensartinib (2) · ivosidenib (2) · larotrectinib (2) · olaparib (2) · palbociclib (2) · selpercatinib (2) · tipifarnib (2) · ulixertinib (2)
National Cancer Institute (NCI) (12) · Children's Oncology Group (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · St. Jude Children's Research Hospital (1) · Theodore Laetsch (1)
United States (16) · Puerto Rico (9) · Canada (5) · Australia (4)
Andrea T Franson (1) · Christine A Pratilas (1) · Crystal L Mackall (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Jacquelyn Crane, MD (1) · Jeremy S Connors, MD (1) · Juan C Vasquez (1) · Julia Glade-Bender (1) · Katherine A Janeway (1) · Kieuhoa T Vo (1) · Kristina A Cole (1) · Meredith S Irwin (1) · Patricio C. Gargollo, M.D. (1) · Rajen Mody (1)
PMID 31401903, PMID 32192573, PMID 33591402, PMID 34486544, PMID 35353553, PMID 38815151, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (10), UM1CA097452 (2), UM1CA228823 (1)